Details
Stereochemistry | ACHIRAL |
Molecular Formula | C25H21N5O3S |
Molecular Weight | 471.531 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1C=C(C=N1)C2=CN=C3C=CC4=CC=C(CS(=O)(=O)NCC5=NC=CC=C5)C=C4C(=O)C3=C2
InChI
InChIKey=VMJFTOSOFDEKTM-UHFFFAOYSA-N
InChI=1S/C25H21N5O3S/c1-30-15-20(13-28-30)19-11-23-24(27-12-19)8-7-18-6-5-17(10-22(18)25(23)31)16-34(32,33)29-14-21-4-2-3-9-26-21/h2-13,15,29H,14,16H2,1H3
Molecular Formula | C25H21N5O3S |
Molecular Weight | 471.531 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/23379595
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23379595
MK-8033 is a dual c-Met/Ron inhibitor, which is under investigation by Merck for the treatment of cancer.
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23379595
Curator's Comment: # Department of Chemistry, Merck & Co., Inc.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2689 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23379595 |
|||
Target ID: CHEMBL3717 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23379595 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
C-Met inhibitor MK-8003 radiosensitizes c-Met-expressing non-small-cell lung cancer cells with radiation-induced c-Met-expression. | 2012 Aug |
|
Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met. | 2013 Mar 28 |
|
A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. | 2013 May |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT00559182
MK-8033 will be administered as an oral formulation in sequentially rising dose levels starting at 50 mg and continuing at 100% dose increments until dose level 4 (800 mg total daily dose). Dose levels 5 to 11 will be escalated at ~40% dose increments until 3000mg (total daily dose). The daily dose of MK-8033 will be divided into two equal doses. MK-8033 will be administered in a first cycle of 14 days (continuous drug administration from Day 1 through Day 14), followed by a 1 week drug holiday (Cycle 1, Day 15 through Day 21). Subsequent cycles of MK-8033 will be administered for 14 days (Cycles 2 to 4) and 28 days (Cycle 5 and beyond).
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22617250
MK-8033 (1 uM) radiosensitized the high-c-Met-expressing EBC-1 and H1993 cells (high-c-Met-expressing non-small cell lung cancers lines,) but not the low-c-Met-expressing cell lines A549 and H460. However, irradiation of A549 and H460 cells increased the expression of c-Met protein at 30 minutes after the irradiation. Subsequent targeting of this up-regulated c-Met by using MK-8033 followed by a second radiation dose reduced the clonogenic survival of both A549 and H460 cells. MK-8033 reduced the levels of radiation-induced phosphorylated (activated) c-Met in A549 cells.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 08:12:32 GMT 2023
by
admin
on
Sat Dec 16 08:12:32 GMT 2023
|
Record UNII |
350H6PBQ5Q
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C116866
Created by
admin on Sat Dec 16 08:12:32 GMT 2023 , Edited by admin on Sat Dec 16 08:12:32 GMT 2023
|
PRIMARY | |||
|
350H6PBQ5Q
Created by
admin on Sat Dec 16 08:12:32 GMT 2023 , Edited by admin on Sat Dec 16 08:12:32 GMT 2023
|
PRIMARY | |||
|
DTXSID00143002
Created by
admin on Sat Dec 16 08:12:32 GMT 2023 , Edited by admin on Sat Dec 16 08:12:32 GMT 2023
|
PRIMARY | |||
|
1196681-38-5
Created by
admin on Sat Dec 16 08:12:32 GMT 2023 , Edited by admin on Sat Dec 16 08:12:32 GMT 2023
|
NO STRUCTURE GIVEN | |||
|
SUB184497
Created by
admin on Sat Dec 16 08:12:32 GMT 2023 , Edited by admin on Sat Dec 16 08:12:32 GMT 2023
|
PRIMARY | |||
|
1001917-37-8
Created by
admin on Sat Dec 16 08:12:32 GMT 2023 , Edited by admin on Sat Dec 16 08:12:32 GMT 2023
|
PRIMARY | |||
|
45142457
Created by
admin on Sat Dec 16 08:12:32 GMT 2023 , Edited by admin on Sat Dec 16 08:12:32 GMT 2023
|
PRIMARY | |||
|
100000170503
Created by
admin on Sat Dec 16 08:12:32 GMT 2023 , Edited by admin on Sat Dec 16 08:12:32 GMT 2023
|
PRIMARY | |||
|
CHEMBL2323775
Created by
admin on Sat Dec 16 08:12:32 GMT 2023 , Edited by admin on Sat Dec 16 08:12:32 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |